Redeye updates its estimates and valuation following MedCap releasing its Q1 2025 report. Sales and adjusted EBITA, as MedCap defines it, roughly aligned with our projections. Assistive Tech delivered strong growth and solid margins for the quarter, while Specialty Pharma continued underperforming. Overall, we judge there are plenty of reasons to believe that MedCap will return to y/y adjusted EBITA growth in Q2 2025e.
LÄS MER
